drugset / Trial / NCT05540262
Edaravone in the Treatment of Optic Neuritis
NaSingle-groupOpen-labelTreatment
Summary
Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.
Timeline
- Start
- 2022-01-15
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Edaravone | Unknown | 30 mg | Other |